Syndax Pharmaceuticals, Inc.

How big is Syndax Pharmaceuticals, Inc.?

As of Jun 18, Syndax Pharmaceuticals, Inc. has a market capitalization of 829.50 million, with net sales of 43.72 million and a net loss of 331.21 million over the latest four quarters. Shareholder's funds are reported at 288.12 million, and total assets amount to 724.82 million.

As of Jun 18, Syndax Pharmaceuticals, Inc. has a market capitalization of 829.50 million, categorizing it as a Small Cap company.<BR><BR>As of Jun 18, the company reported net sales of 43.72 million for the latest four quarters, while the net profit for the same period was a loss of 331.21 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds at 288.12 million and total assets amounting to 724.82 million.

What does Syndax Pharmaceuticals, Inc. do?

Syndax Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing combination therapies for cancer. As of March 2025, it reported net sales of $20 million and a net loss of $85 million, with a market cap of $829.50 million.

Overview:<BR>Syndax Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing combination therapies for multiple cancer indications within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 20 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -85 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 829.50 Million (Small Cap) <BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.78 <BR>Return on Equity: -154.01% <BR>Price to Book: 3.86 <BR><BR>Contact Details:<BR>Address: Building D, 35 Gatehouse Dr Fl 3, WALTHAM MA : 02451-1215 <BR>Tel: 1 781 4191400 <BR>Fax: 1 781 4191420 <BR>Website: http://www.syndax.com/

Should I buy, sell or hold Syndax Pharmaceuticals, Inc.?

Who are in the management team of Syndax Pharmaceuticals, Inc.?

As of March 2022, the management team of Syndax Pharmaceuticals, Inc. includes CEO Dr. Briggs Morrison, President Michael Metzger, and several independent directors, including Mr. Dennis Podlesak as Chairman. They oversee the company's operations and strategic direction.

As of March 2022, the management team of Syndax Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Mr. Dennis Podlesak, Independent Chairman of the Board<BR>- Mr. Michael Metzger, President, Chief Operating Officer, Director<BR>- Dr. Briggs Morrison, Chief Executive Officer, Director<BR>- Dr. Fabrice Egros, Independent Director<BR>- Ms. Jennifer Jarrett, Independent Director<BR>- Mr. Keith Katkin, Independent Director<BR>- Mr. Pierre Legault, Independent Director<BR>- Mr. William Meury, Independent Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Is Syndax Pharmaceuticals, Inc. overvalued or undervalued?

As of August 1, 2024, Syndax Pharmaceuticals is considered risky and overvalued due to its high Price to Book Value of 4.58, negative EV to EBIT and EV to EBITDA ratios, and alarmingly low ROCE and ROE, while it has significantly underperformed the S&P 500 over the past year and three years.

As of 1 August 2024, the valuation grade for Syndax Pharmaceuticals, Inc. has moved from does not qualify to risky, indicating a shift towards a more cautious outlook. The company appears to be overvalued given its high Price to Book Value of 4.58 and negative EV to EBIT and EV to EBITDA ratios of -2.38, which suggest significant operational challenges. Additionally, the Return on Capital Employed (ROCE) and Return on Equity (ROE) are alarmingly low at -730.60% and -154.01%, respectively, further underscoring the company's financial difficulties.<BR><BR>In comparison to its peers, Syndax's P/E ratio is not applicable due to its loss-making status, while Protagonist Therapeutics, Inc. is considered very expensive with a P/E of 67.1750, and Aurinia Pharmaceuticals, Inc. is fairly valued with a P/E of 20.8727. The stock has underperformed against the S&P 500 across multiple periods, with a 1-year return of -14.17% compared to the S&P 500's 17.14%, and a 3-year return of -33.23% versus 70.41% for the index, reinforcing the notion that Syndax is currently overvalued.

Is Syndax Pharmaceuticals, Inc. technically bullish or bearish?

As of September 8, 2025, Syndax Pharmaceuticals, Inc. shows a mildly bearish trend due to mixed signals from various indicators, with underperformance against the S&P 500 over the past week and month.

As of 8 September 2025, the technical trend for Syndax Pharmaceuticals, Inc. has changed from mildly bullish to mildly bearish. The weekly MACD and KST are bullish, while the monthly MACD and KST are bearish, indicating mixed signals across different time frames. The daily moving averages are bullish, but the Bollinger Bands and Dow Theory suggest a bearish stance on the monthly level. The stock has underperformed against the S&P 500 over the past week and month, with returns of -5.62% and -2.65% compared to the S&P's gains of 1.05% and 2.33%, respectively. Overall, the current technical stance is mildly bearish, reflecting weakness in the longer-term indicators.